Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The CLL Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Platinum), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Latest Videos The CLL Sessions Conferences Topics Features Podcasts Expert Editorial Board

Welcome to The Chronic Lymphocytic Leukemia (CLL) Channel

The CLL Channel delivers exciting and topical research in CLL via video interviews, podcasts, roundtable discussions and more. Reporting from key international congresses with world-leading experts, VJHemOnc provides hot topics in CLL such as measurable residual disease (MRD) monitoring, prognostic biomarkers, CAR-T and updates on the use of BTK and BCL-2 inhibitors.

Conferences

iwCLL 2025
SOHO 2025
EHA 2025
ASCO 2025
IBC 2025
CAR-T Meeting 2025
2:34
The IMPROVE trial: paused versus continuous BTKi therapy during vaccination in patients with CLL
Helen Parry • 17 Oct 2025
2:51
Characteristics of patients with CLL who develop immunity following vaccination on BTKi therapy
Helen Parry • 17 Oct 2025
3:15
Managing patients with CLL who relapse after triplet therapy
Jacob Soumerai • 18 Sep 2025
1:29
The optimal duration of time-limited BTKi plus BCL2i combination therapies in CLL
Moritz Fürstenau • 13 Sep 2025
View All Videos
1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
1:43
Advice for young investigators entering the CLL space and key areas of interest
Meghan Thompson • 4 Sep 2025
View All Videos
3:54
The uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL
Adam Kittai • 12 Jun 2025
2:18
Promising agents in the treatment of CLL: BTK degraders and novel BCL2 inhibitors
Jacqueline Barrientos • 19 Jun 2025
5:35
Fixed-duration versus continuous treatment of venetoclax-based regimens in CLL
Jacqueline Barrientos • 19 Jun 2025
1:58
Recent developments in the treatment of Richter’s transformation
Adam Kittai • 12 Jun 2025
View All Videos
1:10
The combination of sonrotoclax and zanubrutinib in MCL and CLL
Constantine Tam • 31 May 2025
2:57
Highlights in NHL and CLL from ASCO 2025: key trial updates
Manali Kamdar • 1 Jun 2025
1:20
Final analysis of the CAPTIVATE study and comparisons with the SEQUOIA trial
Constantine Tam • 31 May 2025
2:12
Five-year follow-up of SEQUOIA Arm C: zanubrutinib in patients with del(17p) CLL
Constantine Tam • 31 May 2025
View All Videos
1:36
Novel testing approaches for the early detection of suspected lymphoproliferative disorders
Anton Langerak • 14 Mar 2025
1:11
The development of new tools to explore the biology of malignant transformation
Sandrine Roulland • 14 Mar 2025
2:11
Understanding the cell of origin and BCR function in CLL
Hendrik Veelken • 14 Mar 2025
1:29
The potential for early interception in MBL: advances and barriers
Anton Langerak • 14 Mar 2025
View All Videos
2:39
The status of CAR T-cell therapy in Brazil and barriers to access
Nelson Hamerschlak • 7 Feb 2025
3:36
Patient-reported side-effects for CAR-T vs other therapies in patients with relapsed lymphomas & CLL
Natacha Bolaños • 7 Feb 2025
2:10
The status of CAR T-cell therapy in acute and chronic leukemias
Ulrich Jäger • 7 Feb 2025
2:19
CAR-T in CLL: updates from the TRANSCEND-CLL-004 trial and when to choose CAR-T for these patients
Tanya Siddiqi • 7 Feb 2025
View All Videos

Topics

MRD
CAR-T & Cellular Therapy
Community Focus
Transplant
Immuno-Oncology
Disease Biology
2:54
Redefining endpoints in CLL clinical trials
Stefano Molica • 13 Sep 2025
2:21
How MRD may reshape the treatment paradigm in CLL
Krzysztof Jamroziak • 23 Sep 2025
3:52
MRD in CLL: technical aspects and clinical significance
Krzysztof Jamroziak • 23 Sep 2025
2:18
MRD-driven venetoclax plus rituximab in previously untreated CLL: the VERITA-PALG-CLL5 trial
Krzysztof Jamroziak • 23 Sep 2025
View All Videos
1:58
The ongoing rapid pace of advancement in CLL: practice-changing developments and promising therapies
Jacob Soumerai • 18 Sep 2025
2:40
A real-world analysis of CNS involvement in CLL
Jacob Soumerai • 18 Sep 2025
1:35
Novel therapies and clinical trial approaches for Richter’s transformation
Catherine Coombs • 9 Sep 2025
3:17
Where will the field of CLL move in the coming years?
Alexey Danilov • 13 Sep 2025
View All Videos
1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
1:43
Advice for young investigators entering the CLL space and key areas of interest
Meghan Thompson • 4 Sep 2025
2:34
The IMPROVE trial: paused versus continuous BTKi therapy during vaccination in patients with CLL
Helen Parry • 17 Oct 2025
3:15
Managing patients with CLL who relapse after triplet therapy
Jacob Soumerai • 18 Sep 2025
View All Videos
2:12
The unmet needs for patients with CLL in the UK and beyond
Nicolas Martinez-Calle • 14 Sep 2025
1:23
The role of transplantation and CAR-T in the treatment of Richter’s transformation
Michel van Gelder • 31 Mar 2025
2:44
The effectiveness of alloSCT after pathway inhibitor treatment in CLL
Michel van Gelder • 31 Mar 2025
2:10
The status of CAR T-cell therapy in acute and chronic leukemias
Ulrich Jäger • 7 Feb 2025
View All Videos
2:51
Characteristics of patients with CLL who develop immunity following vaccination on BTKi therapy
Helen Parry • 17 Oct 2025
3:15
Managing patients with CLL who relapse after triplet therapy
Jacob Soumerai • 18 Sep 2025
2:54
Redefining endpoints in CLL clinical trials
Stefano Molica • 13 Sep 2025
1:10
Combining pirtobrutinib with established regimens for the treatment of CLL
Catherine Coombs • 14 Sep 2025
View All Videos
1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
2:51
Characteristics of patients with CLL who develop immunity following vaccination on BTKi therapy
Helen Parry • 17 Oct 2025
0:49
Improving the understanding of the genetics and biology underlying Richter’s transformation
Erin Parry • 13 Sep 2025
3:15
Approaching frontline therapy selection for different risk groups in CLL
Catherine Coombs • 9 Sep 2025
View All Videos

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Platinum), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Platinum Supporter

AstraZeneca AbbVie

Silver Supporter

BeOne Medicines Lilly

If you are interested in becoming a supporter of The Chronic Lymphocytic Leukemia Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals